Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Therapies and Clinical Outcomes of Chronic Lymphocytic Leukemia
share announcement

Therapies and Clinical Outcomes of Chronic Lymphocytic Leukemia

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 1205

Special Issue Editor

Dr. Sikander Ailawadhi

E-Mail Website
Guest Editor
Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL 32224, USA
Interests: multiple myeloma; healthcare disparities; health services and outcomes research

Special Issue Information

Dear Colleagues,

Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. It is characterized by the accumulation of abnormal lymphocytes, a type of white blood cell, which interfere with the normal functioning of the immune system. Over the years, significant advancements have been made in the treatment of CLL, leading to improved clinical outcomes for patients.

Therapies for CLL include chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation. Chemotherapy involves the use of drugs to kill cancer cells, while targeted therapy uses drugs that specifically target the cancer cells without harming healthy cells. Immunotherapy aims to boost the body's immune system to fight cancer, and stem cell transplantation involves replacing damaged bone marrow with healthy stem cells.

Clinical outcomes in CLL have improved due to the development of novel targeted therapies, such as B-cell receptor inhibitors and BCL-2 inhibitors, which have shown impressive response rates and prolonged survival in clinical trials. Additionally, the advent of chimeric antigen receptor (CAR) T-cell therapy has shown promising results in treating relapsed or refractory CLL.

Moreover, the identification of prognostic factors, such as genetic mutations and chromosomal abnormalities, has enabled personalized treatment approaches for CLL patients. This allows for tailored therapies based on individual risk profiles and disease characteristics.

For this Special Issue, we are pleased to invite you to submit original research articles and comments on any aspect of chronic lymphocytic leukemia.

Dr. Sikander Ailawadhi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chronic lymphocytic leukemia
  • blood and bone marrow
  • abnormal lymphocytes
  • chemotherapy
  • targeted therapy
  • immunotherapy
  • stem cell transplantation
  • prognostic factors

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

20 pages, 2717 KiB  
Article
Increased Frequency of Circulating Activated FOXP3+ Regulatory T Cell Subset in Patients with Chronic Lymphocytic Leukemia Is Associated with the Estimate of the Size of the Tumor Mass, STAT5 Signaling and Disease Course during Follow-Up of Patients on Therapy
by Zlatko Roškar, Mojca Dreisinger, Evgenija Homšak, Tadej Avčin, Sebastjan Bevc and Aleš Goropevšek
Cancers 2024, 16(18), 3228; https://doi.org/10.3390/cancers16183228 - 22 Sep 2024
Viewed by 910
Abstract
Introduction: Advanced chronic lymphocytic leukemia (CLL) is accompanied by increased circulating regulatory T cells (Tregs) and increased susceptibility to severe infections, which were also shown to entail a striking induction of FOXP3 expression in Tregs. As homeostasis of the most suppressive CD45RA− [...] Read more.
Introduction: Advanced chronic lymphocytic leukemia (CLL) is accompanied by increased circulating regulatory T cells (Tregs) and increased susceptibility to severe infections, which were also shown to entail a striking induction of FOXP3 expression in Tregs. As homeostasis of the most suppressive CD45RA−FOXP3high activated Treg (aTreg) subset differs, it is critical to analyse homeostatic signalling in Treg subsets. Materials and Methods: In this study, by using conventional and imaging flow cytometry, we monitored STAT5 signalling/phosphorylation (pSTAT5) and investigated Treg subsets in relation to the Binet stage, the total tumor mass score (TTM) and the disease course during a follow-up of 37 patients with CLL. Results: The aTreg percentage was significantly increased among CD4+ T cells from patients with advanced disease and significantly correlated with the TTM. A subgroup of patients with higher aTreg percentages among CD4+FOXP3+ T cells at the start of therapy was characterised by more frequent episodes of severe infections during follow-up. Conclusions: The results suggesting that an aTreg fraction could represent a possible marker of a severe disease course with infectious complications. Augmented homeostatic STAT5 signalling could support aTreg expansion, as higher pSTAT5 levels were significantly correlated with an increased aTreg frequency among CD4+FOXP3+ T cells during the follow-up of patients on therapy, as well as following SARS-CoV-2 antigen-specific stimulation in vitro. Full article
(This article belongs to the Special Issue Therapies and Clinical Outcomes of Chronic Lymphocytic Leukemia)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop